Skip to main content

Table 1 Baseline characteristics of patients with primary lung cancer who underwent BAE using NBCA and PVA particles

From: Comparison of n-butyl-2-cyanoacrylate and polyvinyl alcohol particles for bronchial artery embolisation in primary lung cancer: a retrospective cohort study

Parameter NBCA group (n = 58) PVA group (n = 64) P-value
Age* (y) 66.5 ± 10.9 65.8 ± 10.3 0.532
Male 47 (81.0) 56 (87.5) 0.454
Haemoptysis grade    0.112
 Grade 3 (> 300 mL) 11 (19.0) 23 (35.9)  
 Grade 2 (100–300 mL) 35 (60.3) 31 (48.4)  
 Grade 1 (≤ 100 mL) 12 (20.7) 10 (15.6)  
Cancer histology (n, %)    0.294
 Adenocarcinoma 20 (34.5) 22 (34.4)  
 Squamous cell carcinoma 23 (39.7) 27 (42.2)  
 “Not otherwise specified” non-small cell lung cancer 7 (12.1) 12 (18.8)  
 Small cell lung cancer 8 (13.8) 3 (4.7)  
Stage    0.848
 IA 2 (3.4) 1 (1.6)  
 IB 2 (3.4) 5 (7.8)  
 IIA 2 (3.4) 2 (3.1)  
 IIB 3 (5.2) 2 (3.1)  
 IIIA 7 (12.1) 10 (15.7)  
 IIIB 14 (24.1) 13 (20.3)  
 IV 28 (48.3) 31 (48.4)  
Mean maximal tumour diameter (mm)* 57.8 ± 30.3 55.6 ± 23.8 0.650
Mass with cavitary lesion 11 (19.0) 8 (12.5) 0.325
Tumour location    0.313
 Central 39 (67.2) 49 (76.6)  
 Peripheral 19 (32.8) 15 (23.4)  
Coagulopathy 6 (10.3) 3 (4.8) 0.309
Hemodynamic instability 10 (17.2) 5 (7.8) 0.167
Previous anticancer treatment    0.492
 Chemotherapy only 21 (36.2) 28 (43.8)  
 Chemoradiation 7 (12.1) 4 (6.2)  
 Radiation only 14 (24.1) 17 (26.6)  
 Surgery 5 (8.6) 8 (12.5)  
 No treatment 11 (19.0) 7 (10.9)  
  1. Data indicate number of patients; percentages are in parenthesis
  2. BAE: bronchial artery embolisation; NBCA: n-butyl-2-cyanoacrylate; PVA: polyvinyl alcohol
  3. *Data are presented as means ± standard deviation